Study tracks biological shifts and systemic changes before menopause
- Biological shifts associated with menopause begin far earlier than the final menstrual period and span multiple bodily systems rather than simply ovarian activity, according to a study published...
- The study found that hormonal changes occur in a distinct sequence well before menstruation stops.
- Follicle-stimulating hormone increases roughly fourteen years prior, while the decline in estradiol becomes more pronounced about twelve years before.
Biological shifts associated with menopause begin far earlier than the final menstrual period and span multiple bodily systems rather than simply ovarian activity, according to a study published on October 12, 2026, in Nature Medicine. Researchers at the Weizmann Institute of Science and other institutions examined roughly 300 million laboratory tests from more than 1.3 million women in the United States and Israel to reconstruct average trajectories relative to the final menstrual period.
The Timeline of Hormonal Shifts
The study found that hormonal changes occur in a distinct sequence well before menstruation stops. Anti-Müllerian hormone, known as AMH and linked to ovarian reserve, drops more rapidly about fifteen years before the final menstrual period.
Follicle-stimulating hormone increases roughly fourteen years prior, while the decline in estradiol becomes more pronounced about twelve years before. These timelines represent population averages rather than individual schedules or symptom markers, according to the research.
Metabolic and Systemic Variations
Out of ninety types of laboratory tests examined, fifty-two showed significant changes clustered around the final menstrual period. These involved variations in bone metabolism, blood lipids, liver parameters, kidney function, and fluid balance.
The body responds across multiple planes rather than uniformly. While markers associated with bone and cardiovascular vulnerability showed increased risk after menopause, other indicators improved, such as ferritin and certain parameters related to anemia following the cessation of menstrual bleeding.
Hormone Therapy and Observation Limits
Women who used menopausal hormone therapy showed less abrupt changes in several laboratory parameters, particularly regarding bone, liver, and kidney markers. However, the study authors noted that this observation does not prove the therapy prevents the corresponding diseases, as treated women may differ in health status, symptoms, and healthcare access.
Clinical guidelines continue to recommend evaluating the menopausal transition through age, symptoms, and cycle patterns rather than routine hormone testing for women over forty-five. The findings emphasize cardiovascular risk awareness, bone health, and physical activity rather than preemptive testing.